Stay updated on Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial
Sign up to get notified when there's something new on the Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial page.

Latest updates to the Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial page
- Check7 days agoChange DetectedRevision: v3.3.3 was added to the release notes, and HHS Vulnerability Disclosure and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedNew Contacts/Locations and Study Status entries were added, and Revision: v3.3.2 was introduced. The previous Revision: v3.3.1 was removed.SummaryDifference0.0%

- Check36 days agoChange DetectedAdded Revision: v3.3.1 and removed Revision: v3.2.0 in the Study Record History. This is a minor update to the revision list.SummaryDifference0.0%

- Check43 days agoChange DetectedNew version on 2025-11-07 adds Contacts/Locations and Study Status, with an earlier 2025-10-28 entry (ID 1046) included. A funding notice from 2025-09-22 was removed.SummaryDifference0.1%

- Check57 days agoChange DetectedThe screenshots show additional history entries for NCT01169337 on the Study Record History page, extending the version history with newer submission dates. These updates are routine record-keeping and do not alter core study information or page functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check86 days agoChange DetectedPage now includes a government-operating-status notice and a new revision tag (v3.2.0), replacing the old revision (v3.0.2).SummaryDifference1%

Stay in the know with updates to Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial page.